🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆ The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape ◆ The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit ◆ The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆ The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape ◆ The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit ◆ The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 11 Jul 2026 · ClinicalTrials.gov

Clinical Trials in Cambridge

← All UK trials

The most recently updated industry-sponsored clinical trials recruiting across the United Kingdom — searchable by condition, sponsor, phase and city. Refreshed daily from the ClinicalTrials.gov registry.

21
Recruiting now
27
Studies tracked
Cambridge
Selected city
Recruiting Phase 2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Gastric Cancer
AstraZeneca · started 2020-06-03
📍 Cambridge · Dundee · London · Manchester · Sutton
NCT04379596 on ClinicalTrials.gov ↗
Active Phase 3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Biliary Tract Cancer
AstraZeneca · started 2023-12-04
📍 Cambridge · Edgbaston · Glasgow, Scotland · London · Manchester
NCT06109779 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc. · started 2023-05-02
📍 Cambridge · Leicester · Manchester · Sutton
NCT05800665 on ClinicalTrials.gov ↗
Active Phase 3
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
Sickle Cell Disease (SCD)
Novartis Pharmaceuticals · started 2019-07-26
📍 Sheffield · Cambridge · London
NCT03814746 on ClinicalTrials.gov ↗
Recruiting Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Amgen · started 2025-07-25
📍 Birmingham · Blackpool · Bristol · Cambridge · Chester
NCT07037433 on ClinicalTrials.gov ↗
Active Phase 2
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
Gaucher Disease Type 1, Gaucher Disease Type 3
Genzyme, a Sanofi Company · started 2017-01-04
📍 Cambridge · Salford
NCT02843035 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves' Disease
Immunovant Sciences GmbH · started 2024-12-17
📍 Birmingham · Bristol · Coventry · London · Cambridge
NCT06727604 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC · started 2025-04-09
📍 Cambridge · Edinburgh · London · Sutton · Leicester
NCT06824467 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
AC Immune SA · started 2022-06-21
📍 Cambridge · Liverpool · London · Oxford · Warrington
NCT05462106 on ClinicalTrials.gov ↗
Recruiting Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Alnylam Pharmaceuticals · started 2025-09-22
📍 Ashburton · Belfast · Bellshill · Birmingham · Bristol
NCT07181109 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC · started 2024-04-03
📍 Cambridge · Northwood · London · Oxford · Newcastle upon Tyne
NCT06312137 on ClinicalTrials.gov ↗
Recruiting Phase 2
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Primary Sjögren's Syndrome
Immunovant Sciences GmbH · started 2025-06-30
📍 Cambridge · Liverpool · London · Swindon · Truro
NCT06979531 on ClinicalTrials.gov ↗
Recruiting Phase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Type 1 Diabetes
SAb Biotherapeutics, Inc. · started 2025-11-25
📍 Cambridge · Cardiff · Edinburgh · Liverpool · London
NCT07187531 on ClinicalTrials.gov ↗
Recruiting Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Bronchiectasis
Boehringer Ingelheim · started 2025-06-09
📍 Belfast · Birmingham · Blackpool · Bradford · Bristol
NCT06872892 on ClinicalTrials.gov ↗
Recruiting Phase 2
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
Osteogenesis Imperfecta (OI)
Angitia Incorporated Limited · started 2025-12-12
📍 Cambridge · Edinburgh · London · Oxford
NCT07062588 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Type 1 Diabetes Mellitus
Sanofi · started 2025-08-06
📍 Cambridge · Dundee · London · Glasgow · Bath
NCT07088068 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics · started 2025-01-28
📍 Aberdeen · Birmingham · Cambridge · Glasgow · Leeds
NCT06788990 on ClinicalTrials.gov ↗
Active Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca · started 2024-03-04
📍 Cambridge · London · Manchester · Oxford · Taunton
NCT06346392 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC · started 2021-05-12
📍 Cambridge · Glasgow · London · Newcastle upon Tyne · Sheffield
NCT07218029 on ClinicalTrials.gov ↗
Recruiting Phase 2
Rescue of Nephrons With ALE.F02 (RENAL-F02)
Glomerulonephritis Rapidly Progressive
Alentis Therapeutics AG · started 2023-09-07
📍 Birmingham · Cambridge · Liverpool · London · Manchester
NCT06047171 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
Solid Tumours
Boehringer Ingelheim · started 2024-12-30
📍 Cambridge · London
NCT06619509 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer · started 2025-10-03
📍 Cambridge · London · Liverpool
NCT06989437 on ClinicalTrials.gov ↗
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd · started 2017-09-12
📍 Belfast · Birmingham · Bristol · Cambridge · Cardiff
NCT03193476 on ClinicalTrials.gov ↗
Recruiting Phase 2
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Lupus Nephritis
Novartis Pharmaceuticals · started 2022-08-10
📍 Cambridge · Leicester
NCT05268289 on ClinicalTrials.gov ↗
Recruiting Phase 1
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd · started 2026-07
📍 Cambridge · Edinburgh · Glasgow · Leeds · Leicester
NCT07665515 on ClinicalTrials.gov ↗
Active Phase 3
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NASH, Cirrhosis, Liver
Madrigal Pharmaceuticals, Inc. · started 2022-08-26
📍 Birmingham · Cambridge · London
NCT05500222 on ClinicalTrials.gov ↗
Recruiting Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC · started 2018-08-21
📍 Aberdeen · Cambridge · Edinburgh · Manchester · Sheffield
NCT03486873 on ClinicalTrials.gov ↗
No trials match your search.

Browse by city

London · 118 Manchester · 30 Glasgow · 27 Cambridge · 27 Birmingham · 24 Leicester · 23 Bristol · 23 Leeds · 22 Sutton · 19 Oxford · 19 Liverpool · 18 Edinburgh · 15 Nottingham · 14 Cardiff · 14 Newcastle upon Tyne · 13 Sheffield · 12

Browse by condition

Obesity · 5 Chronic Lymphocytic Leukemia · 5 Cancer · 4 Breast Neoplasms · 3 Non-small Cell Lung Cancer · 3 Small Lymphocytic Lymphoma · 3 Multiple Myeloma · 3 Hypertension · 3 Heart Failure · 3 Triple Negative Breast Neoplasms · 2 Lymphoma, Non-Hodgkin · 2 Lymphoma, Follicular · 2 Lymphoma, Large B-Cell, Diffuse · 2 Gastric Cancer · 2 Metastatic Prostate Cancer · 2 Overweight · 2
Cite this page

Priya Life Science (2026). Clinical Trials in the UK Tracker. Available at: https://priyalifescience.com/clinical-trials-uk/city/cambridge (Accessed: 11 July 2026).

Source: ClinicalTrials.gov, U.S. National Library of Medicine — industry-sponsored studies in a recruiting status with at least one UK site, most recently updated first, refreshed daily. This is a curated slice of the registry, not every UK trial; UK studies may also be registered on ISRCTN. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. Compare pay for the teams running these studies in our UK Pharma Salary Guide, or see our Ireland, EU and USA trackers.